Insider · CIK 0001815851

Namouni Fouad

Reports to the SEC for 3 companies · BOSTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001815851

Forms 4 and 5

Insider transactions

37 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-11	VORVor Biopharma Inc. · Stock Option (right to buy)A Award	Director	AAward	+56.5K sh	—	—	56,549
2025-07-17	Blueprint Medicines CorpA Award	PRESIDENT, R & D	AAward	+39.5K sh	—	—	115,237
2025-07-17	Blueprint Medicines CorpD Disposition to Issuer	PRESIDENT, R & D	DDisposition to Issuer	−83.3K sh	—	—	31,956
2025-07-17	Blueprint Medicines CorpU Disposition from Tender	PRESIDENT, R & D	UDisposition from Tender	−32K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	PRESIDENT, R & D	DDisposition to Issuer	−65K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	PRESIDENT, R & D	DDisposition to Issuer	−26.1K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	PRESIDENT, R & D	DDisposition to Issuer	−30K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	PRESIDENT, R & D	DDisposition to Issuer	−30K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	PRESIDENT, R & D	DDisposition to Issuer	−30K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	PRESIDENT, R & D	DDisposition to Issuer	−26.4K sh	—	—	0
2025-05-22	VORVor Biopharma Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+30K sh	—	—	30,000
2025-03-05	Blueprint Medicines CorpS Sale	PRESIDENT, R & D	SSale	−6,489 sh	$88.80	−$576K	75,781
2025-03-01	Blueprint Medicines CorpA Award	PRESIDENT, R & D	AAward	+13.2K sh	—	—	82,270
2025-03-01	Blueprint Medicines CorpStock Option (Right to Buy)A Award	PRESIDENT, R & D	AAward	+26.4K sh	—	—	26,400
2024-10-03	Blueprint Medicines CorpS Sale	PRESIDENT, R & D	SSale	−3,633 sh	$89.32	−$324K	69,070
2024-05-23	VORVor Biopharma Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+30K sh	—	—	30,000
2024-04-30	VORVor Biopharma Inc. · Stock Option (right to buy)A Award	Director	AAward	+60K sh	—	—	60,000
2024-03-07	Blueprint Medicines CorpS Sale	PRESIDENT, R & D	SSale	−4,377 sh	$90.69	−$397K	72,703
2024-03-01	Blueprint Medicines CorpA Award	PRESIDENT, R & D	AAward	+15K sh	—	—	77,080
2024-03-01	Blueprint Medicines CorpStock Option (Right to Buy)A Award	PRESIDENT, R & D	AAward	+30K sh	—	—	30,000
2023-10-04	Blueprint Medicines CorpS Sale	PRESIDENT, R & D	SSale	−3,769 sh	$48.06	−$181K	62,080
2023-03-06	Blueprint Medicines CorpS Sale	PRESIDENT, R & D	SSale	−1,885 sh	$45.72	−$86.2K	65,912
2023-03-06	Blueprint Medicines CorpS Sale	PRESIDENT, R & D	SSale	−63 sh	$44.36	−$2,794.68	65,849
2023-03-01	Blueprint Medicines CorpA Award	PRESIDENT, R & D	AAward	+15K sh	—	—	67,797
2023-03-01	Blueprint Medicines CorpStock Option (Right to Buy)A Award	PRESIDENT, R & D	AAward	+30K sh	—	—	30,000
2022-10-04	Blueprint Medicines CorpS Sale	PRESIDENT, R & D	SSale	−3,477 sh	$67.30	−$234K	52,797
2022-03-07	Blueprint Medicines CorpS Sale	PRESIDENT, R & D	SSale	−1,047 sh	$56.19	−$58.8K	56,274
2022-03-01	Blueprint Medicines CorpA Award	PRESIDENT, R & D	AAward	+15K sh	—	—	57,321
2022-03-01	Blueprint Medicines CorpStock Option (Right to Buy)A Award	PRESIDENT, R & D	AAward	+30K sh	—	—	30,000
2021-10-05	Blueprint Medicines CorpS Sale	PRESIDENT, R & D	SSale	−3,241 sh	$98.18	−$318K	42,321
2021-06-30	APREAprea Therapeutics, Inc.A Award	Director	AAward	+4,610 sh	—	—	4,610
2021-06-30	APREAprea Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+22.8K sh	—	—	22,750
2021-03-01	Blueprint Medicines CorpA Award	PRESIDENT, R & D	AAward	+13.1K sh	—	—	45,562
2021-03-01	Blueprint Medicines CorpStock Option (Right to Buy)A Award	PRESIDENT, R & D	AAward	+26.1K sh	—	—	26,125
2020-10-01	Blueprint Medicines CorpA Award	PRESIDENT, R & D	AAward	+32.5K sh	—	—	32,500
2020-10-01	Blueprint Medicines CorpStock Option (Right to Buy)A Award	PRESIDENT, R & D	AAward	+65K sh	—	—	65,000
2020-06-26	APREAprea Therapeutics, Inc. · Stock Option (right to Buy)A Award	Director	AAward	+7,000 sh	—	—	7,000

Recent filings

Accepted (ET)
Jun 124
Namouni Fouad0001193125-26-270000
SEC(opens sec.gov)
Jul 214
Namouni Fouad0001104659-25-069383
SEC(opens sec.gov)
May 234
Namouni Fouad0001415889-25-014525
SEC(opens sec.gov)
Mar 74
Namouni Fouad0001415889-25-007402
SEC(opens sec.gov)
Mar 44
Namouni Fouad0001415889-25-006602
SEC(opens sec.gov)
Oct 44
Namouni Fouad0001415889-24-024776
SEC(opens sec.gov)
May 284
Namouni Fouad0001415889-24-014651
SEC(opens sec.gov)
May 24
Namouni Fouad0001415889-24-012004
SEC(opens sec.gov)
Mar 114
Namouni Fouad0001415889-24-007554
SEC(opens sec.gov)
Mar 64
Namouni Fouad0001415889-24-007021
SEC(opens sec.gov)

Companies

Address

500 BOYLSTON STREET, SUITE 1350

BOSTON, MA, 02116